UnknownPhase 2NCT03209206

The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence

Studying Upper tract urothelial carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seoul National University Hospital
Principal Investigator
Ja Hyeon Ku, M.D.,PH.D
Seoul National University Hospital
Intervention
Docetaxel(drug)
Enrollment
84 target
Eligibility
19-85 years · All sexes
Timeline
2017 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03209206 on ClinicalTrials.gov

Other trials for Upper tract urothelial carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Upper tract urothelial carcinoma →

← Back to all trials